Oculis Holding (OCS) Stock Overview

A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. More details

OCS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 61.12% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

Does not have meaningful revenue (CHF1M)

Volatile share price over the past 3 months compared to the US market

OCS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Oculis Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oculis Holding
Historical stock prices
Current Share Price	US$11.00
52 Week High	US$34.48
52 Week Low	US$10.52
Beta	0.13
1 Month Change	-63.83%
3 Month Change	-56.74%
1 Year Change	-44.11%
3 Year Change	-10.20%
5 Year Change	13.40%
Change since IPO	13.40%

Recent News & Updates

Seeking Alpha • Jun 02

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

Summary Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary and key secondary endpoints. OCS-01 will not move forward for FDA filing in DME, undermining the company's main value driver and casting doubt on its near-term commercial prospects. Attention shifts to pipeline assets Licaminlimab (dry eye disease, Phase 3) and Privosegtor (optic neuropathies), but competitive and data risks remain significant. With $277.6m cash and a >$800m market cap, I remain on the sidelines, unconvinced of a 'Buy the Dip' opportunity until further clinical catalysts materialize. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 02

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

Seeking Alpha • Jan 21

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Summary Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS’s cash runway should last until late 2026, but if they don’t generate an FDA-approved product soon, it could become an issue for shareholders. Still, I see a few catalysts with upcoming regulatory milestones, like an NDA for OCS-01 in Q1, that could help sustain OCS stock’s valuation. I recommend a DCA strategy because Oculis stock might consolidate after such an impressive rally recently. Read the full article on Seeking Alpha

Seeking Alpha • Nov 04

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Summary Oculis has multiple late-stage programs and catalysts. Trading volume is low, and there's hardly any coverage in the US. Barring the low liquidity, OCS looks attractive. Read the full article on Seeking Alpha

Shareholder Returns

	OCS	US Pharmaceuticals	US Market
7D	-7.0%	2.7%	-2.4%
1Y	-44.1%	38.2%	21.5%

Return vs Industry: OCS underperformed the US Pharmaceuticals industry which returned 37.3% over the past year.

Return vs Market: OCS underperformed the US Market which returned 20.6% over the past year.

Price Volatility

Is OCS's price volatile compared to industry and market?
OCS volatility
OCS Average Weekly Movement	15.0%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: OCS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: OCS's weekly volatility has increased from 9% to 15% over the past year.

About the Company

Founded	Employees	CEO	Website
2017	60	Riad Sherif	oculis.com

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.

Oculis Holding AG Fundamentals Summary

How do Oculis Holding's earnings and revenue compare to its market cap?
OCS fundamental statistics
Market cap	US$662.46m
Earnings (TTM)	-US$118.98m
Revenue (TTM)	US$1.41m

470.3x

P/S Ratio

-5.6x

P/E Ratio

Is OCS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCS income statement (TTM)
Revenue	CHF 1.12m
Cost of Revenue	CHF 56.36m
Gross Profit	-CHF 55.24m
Other Expenses	CHF 39.36m
Earnings	-CHF 94.60m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 06, 2026

Earnings per share (EPS)	-1.57
Gross Margin	-4,918.70%
Net Profit Margin	-8,423.51%
Debt/Equity Ratio	0%

How did OCS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 22:04
End of Day Share Price	2026/06/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oculis Holding AG is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Jason Matthew Gerberry	BofA Global Research
Daniil Gataulin	Chardan Capital Markets, LLC

Oculis Holding (OCS) Stock Overview

Rewards

Risk Analysis

Oculis Holding AG Competitors

BioAge Labs

Alto Neuroscience

Relmada Therapeutics

LB Pharmaceuticals

Price History & Performance

Recent News & Updates

Oculis Holding AG Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab

Consensus revenue estimates decrease by 83%

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

New minor risk - Share price stability

Oculis Holding Ag Reports Topline Results from Diamond Phase 3 Trials with Ocs-01 in Diabetic Macular Edema

Oculis Ends Diabetic Eye Drop Program After Phase 3 Setback Refocuses on Pipeline

Recent updates

Oculis Holding AG Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab

Consensus revenue estimates decrease by 83%

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

New minor risk - Share price stability

Oculis Holding Ag Reports Topline Results from Diamond Phase 3 Trials with Ocs-01 in Diabetic Macular Edema

Oculis Ends Diabetic Eye Drop Program After Phase 3 Setback Refocuses on Pipeline

Board Member exercised options to buy US$14k worth of stock.

Oculis Holding Ag Announces Board and Committee Changes

Oculis Holding AG Announces Agreement With FDA on Special Protocol Assessment for Optic Neuritis Registrational Trial

Oculis Holding AG Presents Latest Findings from DME AWARE Delphi Study and Provides Update on OCS-01 Eye Drop Therapy

Oculis Holding AG Announces Completion of Last Patient Visit in Phase 3 Diamond Program with OCS-01 Eye Drops for Treatment of Diabetic Macular Edema

Oculis Holding AG, Annual General Meeting, Mar 23, 2026

Oculis Holding Ag Presents Acuity Phase 2 Data with Privosegtor At North American Neuro-Ophthalmology Society Annual Meeting

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG Appoints Katie Kazem as Chief Legal Officer

Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline

Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis Holding AG to Report Q3, 2026 Results on Nov 05, 2026

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $109.999985 million.

Oculis Holding AG Announces Executive Appointments

Oculis Holding AG, Annual General Meeting, Jun 04, 2025

Oculis Holding AG Hosts R&D Event to Showcase Progress on All Three Pipeline Assets

Oculis Holding AG Completes Enrollment in Both Diamond Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Oculis Holding AG to Report Q4, 2024 Results on Mar 10, 2025

Oculis Announces Positive Topline Results with OCS-05 in the Phase 2 ACUITY Trial

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new and inexperienced directors

Shareholder Returns

Price Volatility

About the Company

Oculis Holding AG Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics